U.K. (FTSE) Pharma Industry Analysis

Industry Valuation and Performance

Has the U.K. Pharma Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 01 Jul 2026	UK£333.8b	UK£92.5b	UK£15.9b	18.4x	21x	3.6x
Fri, 29 May 2026	UK£325.6b	UK£91.9b	UK£15.8b	18.2x	20.6x	3.5x
Sun, 26 Apr 2026	UK£334.5b	UK£90.2b	UK£15.5b	19x	21.6x	3.7x
Tue, 24 Mar 2026	UK£328.0b	UK£90.5b	UK£15.6b	21.1x	21x	3.6x
Thu, 19 Feb 2026	UK£369.1b	UK£90.1b	UK£15.4b	24x	24x	4.1x
Sat, 17 Jan 2026	UK£329.1b	UK£89.7b	UK£14.6b	21.3x	22.5x	3.7x
Mon, 15 Dec 2025	UK£319.1b	UK£89.7b	UK£14.6b	21x	21.8x	3.6x
Wed, 12 Nov 2025	UK£321.4b	UK£90.4b	UK£14.8b	21.9x	21.8x	3.6x
Fri, 10 Oct 2025	UK£303.4b	UK£88.2b	UK£11.8b	19.9x	25.7x	3.4x
Sun, 07 Sep 2025	UK£285.8b	UK£87.5b	UK£11.7b	22x	24.4x	3.3x
Tue, 05 Aug 2025	UK£267.7b	UK£88.2b	UK£11.5b	28.5x	23.3x	3x
Thu, 03 Jul 2025	UK£258.2b	UK£86.0b	UK£10.6b	25.7x	24.4x	3x
Sat, 31 May 2025	UK£271.4b	UK£86.5b	UK£10.6b	27.3x	25.5x	3.1x
Mon, 28 Apr 2025	UK£258.4b	UK£86.4b	UK£9.6b	27.1x	27x	3x
Wed, 26 Mar 2025	UK£277.9b	UK£87.7b	UK£9.7b	32.3x	28.8x	3.2x
Fri, 21 Feb 2025	UK£281.8b	UK£88.7b	UK£9.4b	30.6x	29.9x	3.2x
Sun, 19 Jan 2025	UK£232.8b	UK£76.8b	UK£8.0b	31.8x	29.3x	3x
Tue, 17 Dec 2024	UK£224.3b	UK£74.9b	UK£7.7b	31.5x	29x	3x
Thu, 14 Nov 2024	UK£220.1b	UK£74.9b	UK£7.7b	30.7x	28.5x	2.9x
Sat, 12 Oct 2024	UK£250.3b	UK£72.2b	UK£9.0b	31.1x	27.7x	3.5x
Mon, 09 Sep 2024	UK£271.0b	UK£72.0b	UK£9.0b	40x	30.1x	3.8x
Wed, 07 Aug 2024	UK£262.1b	UK£73.3b	UK£9.1b	37.9x	28.9x	3.6x
Fri, 05 Jul 2024	UK£256.6b	UK£71.4b	UK£9.5b	28.8x	26.9x	3.6x
Sun, 02 Jun 2024	UK£268.8b	UK£71.4b	UK£9.6b	31.8x	28.1x	3.8x
Tue, 30 Apr 2024	UK£262.4b	UK£71.6b	UK£10.0b	32.3x	26.2x	3.7x
Thu, 28 Mar 2024	UK£245.7b	UK£70.7b	UK£9.8b	31.8x	25.2x	3.5x
Sat, 24 Feb 2024	UK£236.1b	UK£70.6b	UK£9.6b	33.7x	24.5x	3.3x
Mon, 22 Jan 2024	UK£238.0b	UK£68.9b	UK£10.7b	36.2x	22.3x	3.5x
Wed, 20 Dec 2023	UK£230.3b	UK£68.8b	UK£10.7b	34.7x	21.6x	3.3x
Fri, 17 Nov 2023	UK£224.4b	UK£69.9b	UK£10.8b	53.4x	20.8x	3.2x
Sun, 15 Oct 2023	UK£245.7b	UK£70.8b	UK£10.4b	56.6x	23.7x	3.5x
Tue, 12 Sep 2023	UK£236.8b	UK£69.6b	UK£10.2b	53.5x	23.1x	3.4x
Thu, 10 Aug 2023	UK£244.1b	UK£69.0b	UK£10.2b	52.8x	24x	3.5x
Sat, 08 Jul 2023	UK£223.4b	UK£67.4b	UK£7.8b	52.7x	28.5x	3.3x

Current Industry PE

Investors are pessimistic on the British Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.

The industry is trading at a PE ratio of 21.0x which is lower than its 3-year average PE of 25.1x.

The industry is trading close to its 3-year average PS ratio of 3.4x.

Past Earnings Growth

The earnings for companies in the Pharmaceuticals industry have grown 27% per year over the last three years.
Revenues for these companies have grown 11% per year.
This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.K. Healthcare industry?


GB Market	0.55%
Healthcare	2.98%
Pharma	3.13%
Pharma	3.13%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
HLN Haleon	UK£3.51	0.7% +UK£220.4m	-5.9%	PE18.5x
HCM HUTCHMED (China)	UK£1.61	0.3% +UK£4.3m	-27.4%	PE4x
EAH ECO Animal Health Group	UK£0.93	5.7% +UK£3.4m	54.2%	PE20.8x
POLB Poolbeg Pharma	UK£0.069	2.2% +UK£1.1m	110.8%	PB5.6x
ANCR Animalcare Group	UK£3.32	0.2% +UK£345.2k	12.5%	PE45.1x

Futura Medical Reports Highly Positive Data From WSD4000 Studies

Futura Medical reported the results from two studies on WSD4000: the Home User Test ('HUT') and the Placebo (Sham) Controlled Study. The positive results from both studies enhance the Company's belief in the commercial potential for WSD4000 and demonstrate that WSD4000 is superior to placebo (sham) thereby enabling it to proceed with the clinical study with high confidence of success. The Company expects to commence the clinical study by the end of 2026, subject to additional funding. WSD4000 was evaluated in 228 pre-, peri or post-menopausal women over a 4-week period. The results demonstrated that WSD4000 markedly improved sexual function from using the product. 78% of women reported a general improvement in all or most aspects of sex. 78% reported a more satisfying experience and 75% noticed having some increase in interest in having sex; 81% noticed an improvement to their overall sexual function. Overall, 68% of women rated the product 4 or 5 stars. 77% of participants had improved sexual experience after one use which increased to 84% after four uses. More specifically, after four uses: 83% of women experienced improved lubrication (wetness), 82% experienced improved genital sensation, 75% experienced improved arousal, 71% experienced faster arousal, 66% experienced greater ability to achieve orgasm, 61% experienced greater intensity of orgasm, 58% experienced less pain and discomfort during sex. The study also showed that, in general, the product was well tolerated, with only 18% of women experiencing a transient unpleasant sensory effect but many of those still wished to continue to use the product. The sensory effect described as unpleasant in some subjects can be mitigated when commercialised by clear consumer explanation highlighting that this is part of the mode of action of the product. The vast majority (84%) of women in the study claimed to like the sensory feel and lack of aroma of the product. A placebo ('sham' in US regulatory terminology) controlled study was conducted in order to design the most cost-effective clinical study to deliver a statistically significant and clinically meaningful result. WSD4000 was evaluated versus a placebo control in an "in-clinic" cross-over study in 33 pre- and post-menopausal women. WSD4000 was statistically superior to placebo in each of the key measures (arousal, genital sensation and lubrication) at 1 min, 2 min, 3 min, 5 min, 10 min and 15 min intervals. The results give the Company a high degree of confidence that WSD4000 will have superior efficacy to placebo (sham) in the pivotal clinical study and that subject numbers in the study will be at a cost-effective level. Independent research data conducted in the US with 1,000 subjects shows that 60% of women have suffered from at least one symptom of impaired sexual response and function in the prior twelve months. Only 1 in 4 of those impacted women seek professional help. Few women (13%) experience an improvement in symptoms over time and for 37% symptoms get worse over time. Currently, there is no known regulatory approved topical treatment globally for impaired sexual response and function in women that is available over the counter. Market research conducted by Ipsos showed 60% of women have experienced symptoms of sexual dysfunction over the last twelve months and 49% of women want to treat their symptoms. Current US female population between the ages of 22 and 75 is 113 million, of which 68 million experience symptoms. WSD4000 is a project name for our development female sexual health portfolio, starting with the creation of a range of topical gels under our unique platform technology, specifically designed to treat symptoms of sexual dysfunction in women. There is currently no known regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal, lubrication and ability to orgasm.

U.K. (FTSE) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Futura Medical Reports Highly Positive Data From WSD4000 Studies

HUTCHMED (China) Limited to Report First Half, 2026 Results on Jul 30, 2026

Astrazeneca Reports Positive MULBERRY Phase III Results For Efzimfotase Alfa In Pediatric Hypophosphatasia

Poolbeg Pharma Receives Patent Grant for POLB 001 in South Africa for Treatment or Prevention of Hypercytokinemia and Severe Influenza

EAH: Higher Profitability Assumptions Will Support Stronger Future Share Performance

FDA Approves Utebzi as First Oral Carbapenem Antibiotic for Complicated UTIs in Adults

Sareum Holdings PLC Publishes Phase 1 Clinical Data on SDC-1801 in British Journal Of Clinical Pharmacology

Hikma Pharmaceuticals PLC Welcomes FDA Approval of Guardant360 Liquid CDx

Immupharma Reports University of Murcia Research on P140 Peptide in Glioblastoma

STX: Pediatric And Pulmonary Hypertension Trials Will Support Future Upside

Animalcare Group plc Announces Appointment of Els Leen Veerle Degroote as Director, Effective June 12, 2026

HLN: Cautious Ratings And Execution Progress Will Guide Future Share Price

Allergy Therapeutics plc Presents Data From Pollen And Food Allergy Research Portfolio And Hosts Symposium At EAACI Congress 2026

New major risk - Shareholder dilution